- Home
- OP vs HSCS Comparison
OP vs HSCS Comparison
Compare OP & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- HSCS
- Stock Information
- Founded
- OP 2021
- HSCS 2007
- Country
- OP Greece
- HSCS United States
- Employees
- OP N/A
- HSCS N/A
- Industry
- OP
- HSCS Medical Specialities
- Sector
- OP
- HSCS Health Care
- Exchange
- OP Nasdaq
- HSCS Nasdaq
- Market Cap
- OP 8.6M
- HSCS 9.9M
- IPO Year
- OP N/A
- HSCS 2022
- Fundamental
- Price
- OP $1.38
- HSCS $3.64
- Analyst Decision
- OP
- HSCS Strong Buy
- Analyst Count
- OP 0
- HSCS 2
- Target Price
- OP N/A
- HSCS $10.50
- AVG Volume (30 Days)
- OP 260.2K
- HSCS 94.3K
- Earning Date
- OP 08-08-2025
- HSCS 09-11-2025
- Dividend Yield
- OP N/A
- HSCS N/A
- EPS Growth
- OP N/A
- HSCS N/A
- EPS
- OP N/A
- HSCS N/A
- Revenue
- OP $19,435,000.00
- HSCS $6,250.00
- Revenue This Year
- OP N/A
- HSCS $13,968.97
- Revenue Next Year
- OP N/A
- HSCS $166.67
- P/E Ratio
- OP N/A
- HSCS N/A
- Revenue Growth
- OP N/A
- HSCS N/A
- 52 Week Low
- OP $1.07
- HSCS $2.52
- 52 Week High
- OP $79.25
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- OP 61.93
- HSCS 52.75
- Support Level
- OP $1.22
- HSCS $3.57
- Resistance Level
- OP $1.33
- HSCS $3.77
- Average True Range (ATR)
- OP 0.07
- HSCS 0.17
- MACD
- OP -0.01
- HSCS 0.02
- Stochastic Oscillator
- OP 75.25
- HSCS 57.50
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.